Lithium, administered to patients of bipolar disorders, is mainly excreted into urine, and tubular reabsorption at the proximal tubule is involved in the renal handling of lithium. In this study, we examined the renal excretion of lithium in rats with Fanconi syndrome, characterized by defects of transports of various compounds at the proximal tubules, induced by maleic acid. After maleic acid was intravenously injected, mannitol and lithium chloride were infused in turn. Using samples of plasma and bladder urine during the mannitol infusion, renal parameters were determined. Pharmacokinetic parameters of lithium were obtained using samples during the lithium chloride infusion. Maleic acid decreased creatinine clearance and increased the fractional excretion of glucose and phosphate, suggesting the induction of Fanconi syndrome. In rats with Fanconi syndrome, plasma concentration of lithium was increased, and its renal clearance was decreased. No effect on the fractional excretion of lithium was exhibited. This study represents that the tubular reabsorption of lithium was impaired to the same degree with glomerular filtration in rats with experimental Fanconi syndrome and that the dysfunction of the tubular reabsorption of glucose and phosphate was more severe. It is possible that Fanconi syndrome inhibited the reabsorption of lithium at the proximal tubule and facilitated the reabsorption of lithium from the loop of Henle to the collecting duct.

1.
Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium.
Clin Pharmacokinet
. 1995 Sep;29(3):172–91.
2.
Price LH, Heninger GR. Lithium in the treatment of mood disorders.
N Engl J Med
. 1994 Sep;331(9):591–8.
3.
Shirley DG, Walter SJ, Sampson B. A micropuncture study of renal lithium reabsorption: effects of amiloride and furosemide.
Am J Physiol
. 1992 Dec;263(6 Pt 2):F1128–33.
4.
Uwai Y, Arima R, Takatsu C, Furuta R, Kawasaki T, Nabekura T. Sodium-phosphate cotransporter mediates reabsorption of lithium in rat kidney.
Pharmacol Res
. 2014 Sep;87:94–8.
5.
Hartmann A, Holdaas H, Steen PA, Kiil F. Evidence for bicarbonate-dependent lithium reabsorption in dog kidneys.
Acta Physiol Scand
. 1984 Feb;120(2):257–64.
6.
Finley PR. Drug interactions with lithium: an update.
Clin Pharmacokinet
. 2016 Aug;55(8):925–41.
7.
Thomsen K, Schou M. Renal lithium excretion in man.
Am J Physiol
. 1968 Oct;215(4):823–7.
8.
Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi's syndrome.
Am J Kidney Dis
. 2003 Feb;41(2):292–309.
9.
Foreman JW. Fanconi syndrome.
Pediatr Clin North Am
. 2019 Feb;66(1):159–67.
10.
Al-Bander H, Etheredge SB, Paukert T, Humphreys MH, Morris RC Jr. Phosphate loading attenuates renal tubular dysfunction induced by maleic acid in the dog.
Am J Physiol
. 1985 Apr;248(4 Pt 2):F513–21.
11.
Eiam-ong S, Spohn M, Kurtzman NA, Sabatini S. Insights into the biochemical mechanism of maleic acid-induced Fanconi syndrome.
Kidney Int
. 1995 Nov;48(5):1542–8.
12.
Nissim I, Weinberg JM. Glycine attenuates Fanconi syndrome induced by maleate or ifosfamide in rats.
Kidney Int
. 1996 Mar;49(3):684–95.
13.
Lang F. Osmotic diuresis.
Ren Physiol
. 1987;10(3–4):160–73.
14.
Ohashi N, Aoki T, Matsuyama T, Ishigaki S, Isobe S, Fujikura T, et al. Sodium-glucose cotransporter-2 inhibitor immediately decreases serum uric acid levels in type 2 diabetic patients.
Med Sci Monit
. 2020 Oct 2;26:e926086.
15.
Uwai Y, Matsumoto M, Kawasaki T, Nabekura T. Enantioselective effect of flurbiprofen on lithium disposition in rats.
Pharmacology
. 2017;99(5–6):236–9.
16.
Uwai Y, Suzuki T, Kondo R, Kawasaki T, Nabekura T. Effect of renal ischemia on urinary excretion of lithium in rats.
Biopharm Drug Dispos
. 2018 Nov;39(9):448–51.
17.
Thomsen K, Shirley DG. The validity of lithium clearance as an index of sodium and water delivery from the proximal tubules.
Nephron
. 1997;77(2):125–38.
18.
Seidlerová J, Staessen JA, Maillard M, Nawrot T, Zhang H, Bochud M, et al. Association between arterial properties and renal sodium handling in a general population.
Hypertension
. 2006 Oct;48(4):609–15.
19.
Aronson PS, Giebisch G. Mechanisms of chloride transport in the proximal tubule.
Am J Physiol
. 1997 Aug;273(2 Pt 2):F179–92.
20.
Knauf F, Yang CL, Thomson RB, Mentone SA, Giebisch G, Aronson PS. Identification of a chloride-formate exchanger expressed on the brush border membrane of renal proximal tubule cells.
Proc Natl Acad Sci U S A
. 2001 Jul;98(16):9425–30.
21.
Günther R, Silbernagl S, Deetjen P. Maleic acid induced aminoaciduria, studied by free flow micropuncture and continuous microperfusion.
Pflugers Arch
. 1979 Nov;382(2):109–14.
22.
Leyssac PP, Frederiksen O, Holstein-Rathlou NH, Alfrey AC, Christensen P. Active lithium transport by rat renal proximal tubule: a micropuncture study.
Am J Physiol
. 1994 Jul;267(1 Pt 2):F86–93.
23.
Koomans HA, Boer WH, Dorhout Mees EJ. Evaluation of lithium clearance as a marker of proximal tubule sodium handling.
Kidney Int
. 1989 Jul;36(1):2–12.
24.
Cogen MG. Disorders of proximal nephron function.
Am J Med
. 1982 Feb;72(2):275–88.
25.
Yukawa E, Nomiyama N, Higuchi S, Aoyama T. Lithium population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.
Ther Drug Monit
. 1993 Apr;15(2):75–82.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.